Form 4: RA Capital Management Sells 165K Shares of Vor Biopharma

RA Capital Management, a major shareholder and director-affiliated entity, sold 165,150 shares of Vor Biopharma Inc. at a weighted average price of $15.77.

Summary

• RA Capital Management, L.P. reported the sale of 165,150 shares of Vor Biopharma Inc. (VOR) common stock.
• The transaction occurred on April 22, 2026, at a weighted average price of $15.77 per share.
• Following the sale, the reporting entities maintain beneficial ownership of 2,402,095 shares.
• The shares were sold in multiple transactions with prices ranging from $15.75 to $15.85.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a standard regulatory disclosure of an institutional portfolio adjustment rather than a fundamental change in company operations.

Positives

• The sale represents a partial divestment by a major institutional holder, which can sometimes improve liquidity for other market participants.

Negatives

• The sale of shares by a 10% owner and director-affiliated entity may be perceived by some investors as a lack of long-term confidence in the immediate share price appreciation.

Risks

• Continued selling pressure from major institutional shareholders could negatively impact the stock price.

Future Outlook

No specific forward-looking guidance regarding company operations or financial performance was provided in this filing.

Management Comments

• The reporting persons have committed to providing full information regarding the number of shares sold at each separate price within the reported range upon request.

Industry Context

StockSavvy.ai notes that institutional divestment in the biotech sector is common for portfolio rebalancing, though it is closely monitored by retail investors for signals regarding institutional sentiment toward clinical-stage companies.

Comparison to Industry Standards

• Institutional selling by venture-backed biotech firms is standard practice as funds reach maturity or rebalance risk exposure.
• The transaction size is relatively small compared to the total outstanding shares, suggesting a routine portfolio adjustment rather than a strategic exit.

Stakeholder Impact

• Shareholders may experience minor volatility due to the institutional sale.

Next Steps

• Monitor future Form 4 filings to determine if RA Capital continues to reduce its position.

Key Dates

Keywords

Vor Biopharma, VOR, RA Capital Management, Insider Trading, Form 4, Biotech, Equity Sale